Table 2.

Hugo_Symbol	Variant_Classification	RegID	LGL_Type
ABCC9	Missense_Mutation	1844	T
ABCC9	Missense_Mutation	2108	T
ABCC9	Missense_Mutation	2022	T
ABCC9	Missense_Mutation	2062	T
ABCC9	Nonsense_Mutation	2127	T
ADAMTSL1	Missense_Mutation	2119	T
ADAMTSL1	Missense_Mutation	2207	T
ADAMTSL1	Missense_Mutation	2081	T
ADAMTSL1	Splice_Region	2051	T
ARHGAP25	Missense_Mutation	2103	T
ARHGAP25	Frame_Shift_Del	2103	T
ARHGAP25	Frame_Shift_Del	2049	T
ARHGAP25	Frame_Shift_Ins	2157	GD
ARNT2	Missense_Mutation	2135	T
ARNT2	Missense_Mutation	1888	GD
ARNT2	Missense_Mutation	2127	T
ASXL3	Missense_Mutation	2214	T
ASXL3	Missense_Mutation	2074	T
ASXL3	Missense_Mutation	2090	GD
C2orf71	Missense_Mutation	2217	T
C2orf71	Missense_Mutation	2107	T
C2orf71	Missense_Mutation	2214	T
CACNA1E	Missense_Mutation	1499	T
CACNA1E	Missense_Mutation	2190	T
CACNA1E	Missense_Mutation	2022	T
CACNA2D3	Missense_Mutation	1844	T
CACNA2D3	Missense_Mutation	2225	T
CACNA2D3	Missense_Mutation	1822	GD
CAD	Missense_Mutation	1918	T
CAD	Missense_Mutation	2074	T
CAD	Splice_Region	2090	GD
CDH20	Missense_Mutation	1544	T
CDH20	Missense_Mutation	2200	T
CDH20	Missense_Mutation	1796	T
CHD9	Splice_Region	2200	T
CHD9	Missense_Mutation	2098	T
CHD9	Nonsense_Mutation	2062	T
CHD9	Missense_Mutation	2127	T
CNTNAP2	Missense_Mutation	2084	T
CNTNAP2	Splice_Region	1955	T
CNTNAP2	Missense_Mutation	2127	T
COL11A1	Splice_Site	2205	T
COL11A1	Missense_Mutation	2205	T
COL11A1	Splice_Region	2169	T
COL11A1	Missense_Mutation	2037	T
COL11A1	Missense_Mutation	2146	T
COL11A1	Splice_Region	2127	T
COL24A1	Nonsense_Mutation	2049	T
COL24A1	Missense_Mutation	1718	T
COL24A1	Splice_Region	2051	T
COL3A1	Splice_Region	2042	T
COL3A1	Nonsense_Mutation	2191	T
COL3A1	Missense_Mutation	1798	T
CSMD3	Nonsense_Mutation	2205	T
CSMD3	Missense_Mutation	2049	T
CSMD3	Missense_Mutation	2214	T
CUX2	Splice_Region	2249	T
CUX2	Missense_Mutation	1974	T
CUX2	Missense_Mutation	2051	T
DAPK1	Missense_Mutation	2095	T
DAPK1	Missense_Mutation	2042	T
DAPK1	Missense_Mutation	2082	T
DDX59	Missense_Mutation	2108	T
DDX59	Missense_Mutation	2049	T
DDX59	Missense_Mutation	2084	T
DDX59	Missense_Mutation	2084	T
DMD	Missense_Mutation	2249	T
DMD	Splice_Region	2204	T
DMD	Missense_Mutation	2042	T
DMD	Missense_Mutation	1999	T
DNAH5	Missense_Mutation	1822	GD
DNAH5	Missense_Mutation	2157	GD
DNAH5	Missense_Mutation	2127	T
DNER	Missense_Mutation	1715	T
DNER	Splice_Region	2081	T
DNER	Splice_Site	2062	T
DNMT3A	Missense_Mutation	2226	T
DNMT3A	Missense_Mutation	2135	T
DNMT3A	Missense_Mutation	1549	T
DSCAM	Missense_Mutation	2214	T
DSCAM	Missense_Mutation	2186	GD
DSCAM	Missense_Mutation	2146	T
EPHA7	Splice_Region	1746	T
EPHA7	Missense_Mutation	1970	T
EPHA7	Missense_Mutation	2051	T
EYS	Missense_Mutation	2214	T
EYS	Missense_Mutation	2105	T
EYS	Missense_Mutation	1906	T
EYS	Missense_Mutation	2090	GD
FAS	Nonsense_Mutation	2249	T
FAS	Frame_Shift_Del	2056	T
FAS	Splice_Region	2077	T
FAS	Missense_Mutation	2077	T
FAT3	Missense_Mutation	2042	T
FAT3	Missense_Mutation	2084	T
FAT3	Missense_Mutation	2169	T
FAT3	Missense_Mutation	2062	T
FAT4	Missense_Mutation	1918	T
FAT4	Missense_Mutation	2228	T
FAT4	Missense_Mutation	1688	T
FAT4	Missense_Mutation	1798	T
FSIP2	Missense_Mutation	2202	T
FSIP2	Missense_Mutation	2251	T
FSIP2	Missense_Mutation	2074	T
FSTL5	Missense_Mutation	1945	T
FSTL5	Missense_Mutation	2009	T
FSTL5	Missense_Mutation	2225	T
GLI3	Missense_Mutation	1718	T
GLI3	Missense_Mutation	2051	T
GLI3	Nonsense_Mutation	2127	T
GRID2	Splice_Region	2164	T
GRID2	Missense_Mutation	1822	GD
GRID2	Missense_Mutation	2127	T
HERC2	Nonsense_Mutation	2249	T
HERC2	Missense_Mutation	2042	T
HERC2	Frame_Shift_Del	2146	T
HRNR	Missense_Mutation	2174	T
HRNR	Missense_Mutation	2037	T
HRNR	Missense_Mutation	2146	T
HTT	Missense_Mutation	2107	T
HTT	In_Frame_Del	2165	T
HTT	Missense_Mutation	1960	GD
ITGAL	Missense_Mutation	1844	T
ITGAL	Splice_Region	2042	T
ITGAL	Missense_Mutation	2152	T
ITGAL	Splice_Region	1549	T
KDM6A	Nonsense_Mutation	2173	T
KDM6A	Missense_Mutation	1544	T
KDM6A	Splice_Region	2214	T
KDM6A	Frame_Shift_Del	1798	T
KIAA0196	Missense_Mutation	2083	GD
KIAA0196	Missense_Mutation	1822	GD
KIAA0196	Missense_Mutation	1549	T
KMT2D	Nonsense_Mutation	2249	T
KMT2D	Frame_Shift_Del	2207	T
KMT2D	Nonsense_Mutation	2207	T
KMT2D	Frame_Shift_Del	2225	T
KMT2D	In_Frame_Del	2029	T
KMT2D	Nonsense_Mutation	2042	T
KMT2D	Frame_Shift_Del	2105	T
KMT2D	Nonsense_Mutation	2147	T
KMT2D	Nonsense_Mutation	2074	T
KMT2D	Frame_Shift_Ins	2090	GD
KMT2D	Missense_Mutation	2051	T
KMT2D	Splice_Site	2127	T
KY	Missense_Mutation	1844	T
KY	Nonsense_Mutation	1895	T
KY	Splice_Region	2157	GD
LAMC3	Missense_Mutation	2135	T
LAMC3	Missense_Mutation	1822	GD
LAMC3	Splice_Region	1974	T
MUC16	Missense_Mutation	2205	T
MUC16	Missense_Mutation	2107	T
MUC16	Missense_Mutation	2103	T
MUC16	Missense_Mutation	1955	T
MYO18B	Missense_Mutation	1499	T
MYO18B	Missense_Mutation	2042	T
MYO18B	Missense_Mutation	2074	T
MYO18B	Missense_Mutation	2127	T
NCKAP5	Missense_Mutation	1544	T
NCKAP5	Missense_Mutation	2249	T
NCKAP5	Missense_Mutation	1549	T
NCKAP5	Missense_Mutation	2144	T
NDST3	Missense_Mutation	2103	T
NDST3	Missense_Mutation	1746	T
NDST3	Missense_Mutation	1822	GD
NRP2	Missense_Mutation	1544	T
NRP2	Missense_Mutation	2107	T
NRP2	Splice_Site	2049	T
OLFML2A	Missense_Mutation	2135	T
OLFML2A	Missense_Mutation	2180	T
OLFML2A	Missense_Mutation	2157	GD
OTOG	Missense_Mutation	2208	GD
OTOG	Missense_Mutation	2207	T
OTOG	Missense_Mutation	1746	T
PCDH11X	Missense_Mutation	2205	T
PCDH11X	Missense_Mutation	2228	T
PCDH11X	Missense_Mutation	1970	T
PCDH15	Missense_Mutation	1970	T
PCDH15	Missense_Mutation	2191	T
PCDH15	Missense_Mutation	2074	T
PCDHA11	Missense_Mutation	1544	T
PCDHA11	Missense_Mutation	1888	GD
PCDHA11	Missense_Mutation	2042	T
PCLO	Missense_Mutation	1844	T
PCLO	Missense_Mutation	1746	T
PCLO	Missense_Mutation	2152	T
PCLO	Missense_Mutation	2051	T
PIK3R1	In_Frame_Del	2249	T
PIK3R1	Missense_Mutation	1746	T
PIK3R1	Missense_Mutation	2247	GD
PIK3R1	Missense_Mutation	2143	T
RYR2	Missense_Mutation	2173	T
RYR2	Missense_Mutation	1945	T
RYR2	Missense_Mutation	1544	T
RYR2	Missense_Mutation	2251	T
RYR2	Nonsense_Mutation	1895	T
RYR2	Missense_Mutation	2074	T
SALL3	Missense_Mutation	2165	T
SALL3	Missense_Mutation	1549	T
SALL3	Missense_Mutation	2127	T
SETD1B	Splice_Site	1544	T
SETD1B	In_Frame_Del	2228	T
SETD1B	Missense_Mutation	2214	T
SETD1B	Splice_Site	2074	T
SETD1B	Splice_Site	1974	T
SETD1B	Frame_Shift_Del	2127	T
SLC6A15	Missense_Mutation	1918	T
SLC6A15	Missense_Mutation	2074	T
SLC6A15	Missense_Mutation	1999	T
SLC6A15	Missense_Mutation	2051	T
SMAD6	In_Frame_Del	2174	T
SMAD6	Frame_Shift_Del	2174	T
SMAD6	Nonsense_Mutation	2126	T
SMAD6	Missense_Mutation	1955	T
SORCS3	Splice_Site	1499	T
SORCS3	Missense_Mutation	1746	T
SORCS3	Missense_Mutation	2042	T
SRRM2	Missense_Mutation	2228	T
SRRM2	Missense_Mutation	1822	GD
SRRM2	Missense_Mutation	2090	GD
SSC5D	Missense_Mutation	1948	T
SSC5D	Missense_Mutation	1822	GD
SSC5D	Missense_Mutation	1974	T
STAT3	Missense_Mutation	1715	T
STAT3	Missense_Mutation	1499	T
STAT3	Missense_Mutation	1474	T
STAT3	Missense_Mutation	1918	T
STAT3	Missense_Mutation	2020	T
STAT3	Missense_Mutation	1544	T
STAT3	Missense_Mutation	2205	T
STAT3	Missense_Mutation	1849	T
STAT3	Missense_Mutation	2208	GD
STAT3	Missense_Mutation	2249	T
STAT3	Missense_Mutation	2056	T
STAT3	Missense_Mutation	2228	T
STAT3	Missense_Mutation	2108	T
STAT3	Missense_Mutation	2103	T
STAT3	Missense_Mutation	2207	T
STAT3	Missense_Mutation	2207	T
STAT3	Missense_Mutation	2049	T
STAT3	Missense_Mutation	2139	T
STAT3	Missense_Mutation	2139	T
STAT3	Missense_Mutation	1746	T
STAT3	Missense_Mutation	1970	T
STAT3	Missense_Mutation	2180	T
STAT3	Missense_Mutation	1796	T
STAT3	Missense_Mutation	1718	T
STAT3	Missense_Mutation	2151	T
STAT3	Missense_Mutation	2225	T
STAT3	Missense_Mutation	2174	T
STAT3	Missense_Mutation	1888	GD
STAT3	Missense_Mutation	2095	T
STAT3	Missense_Mutation	2126	T
STAT3	Missense_Mutation	2214	T
STAT3	Missense_Mutation	2042	T
STAT3	Missense_Mutation	2110	T
STAT3	Missense_Mutation	2084	T
STAT3	Missense_Mutation	2105	T
STAT3	Missense_Mutation	2251	T
STAT3	Missense_Mutation	2147	T
STAT3	Missense_Mutation	1985	T
STAT3	Missense_Mutation	2190	T
STAT3	Missense_Mutation	2152	T
STAT3	Missense_Mutation	2152	T
STAT3	Missense_Mutation	2082	T
STAT3	Missense_Mutation	2164	T
STAT3	Missense_Mutation	2022	T
STAT3	Missense_Mutation	1798	T
STAT3	Missense_Mutation	2074	T
STAT3	Missense_Mutation	2090	GD
STAT3	Missense_Mutation	2081	T
STAT3	Missense_Mutation	2062	T
STAT3	Missense_Mutation	2037	T
STAT3	Missense_Mutation	1974	T
STAT3	Missense_Mutation	2144	T
STAT3	Missense_Mutation	2051	T
STAT3	Missense_Mutation	2157	GD
STAT3	Missense_Mutation	2157	GD
STAT3	Missense_Mutation	2077	T
STAT3	Missense_Mutation	2127	T
STAT5B	Missense_Mutation	1844	T
STAT5B	Missense_Mutation	1895	T
STAT5B	Missense_Mutation	1822	GD
SULF1	Missense_Mutation	1844	T
SULF1	Missense_Mutation	2009	T
SULF1	Missense_Mutation	2049	T
SULF1	Missense_Mutation	1822	GD
SVEP1	Missense_Mutation	1888	GD
SVEP1	Missense_Mutation	2074	T
SVEP1	Missense_Mutation	2051	T
SYNJ1	Missense_Mutation	2029	T
SYNJ1	Missense_Mutation	2110	T
SYNJ1	Missense_Mutation	2105	T
TENM3	Splice_Site	1499	T
TENM3	Missense_Mutation	1544	T
TENM3	Missense_Mutation	1746	T
TENM3	Missense_Mutation	2191	T
TET2	Frame_Shift_Del	2228	T
TET2	Frame_Shift_Del	2207	T
TET2	Frame_Shift_Del	2049	T
TET2	Nonsense_Mutation	2126	T
TET2	Nonsense_Mutation	2251	T
TNFAIP3	Nonsense_Mutation	1544	T
TNFAIP3	Frame_Shift_Del	2249	T
TNFAIP3	Missense_Mutation	2249	T
TNFAIP3	Nonsense_Mutation	2139	T
TNFAIP3	Frame_Shift_Ins	2145	T
TNFAIP3	Frame_Shift_Del	2145	T
TNFAIP3	Nonsense_Mutation	2125	T
TNFAIP3	Frame_Shift_Del	2082	T
TNFAIP3	Frame_Shift_Ins	2074	T
TNFAIP3	Missense_Mutation	2081	T
TNFAIP3	Frame_Shift_Del	2037	T
TTN	Missense_Mutation	2205	T
TTN	Missense_Mutation	2153	T
TTN	Missense_Mutation	2110	T
TTN	Missense_Mutation	2251	T
TTN	Missense_Mutation	2190	T
TTN	Missense_Mutation	1960	GD
TTN	Missense_Mutation	2081	T
USH2A	Missense_Mutation	2173	T
USH2A	Missense_Mutation	2205	T
USH2A	Missense_Mutation	2122	T
USH2A	Missense_Mutation	2207	T
USH2A	Missense_Mutation	2225	T
USH2A	Missense_Mutation	2125	T
USH2A	Splice_Region	2152	T
VCAN	Missense_Mutation	1844	T
VCAN	Missense_Mutation	2214	T
VCAN	Missense_Mutation	2125	T
VCAN	Missense_Mutation	2077	T
WDFY3	Nonsense_Mutation	2139	T
WDFY3	Missense_Mutation	2147	T
WDFY3	Splice_Region	1549	T
XIRP2	Missense_Mutation	2202	T
XIRP2	Missense_Mutation	2084	T
XIRP2	Missense_Mutation	2105	T
ZNF585B	Missense_Mutation	2174	T
ZNF585B	Missense_Mutation	2214	T
ZNF585B	Missense_Mutation	2022	T

Supplemental Table 2.

Genes that are mutated in three or more patients in the cohort are shown.

Table 3.

Oligonucleotide primer list
PCR Target	RefSeq Accession No.	Detected Coding Transcript(s)	BioRad Unique Assay ID	Amplicon Context Sequence
ZBTB46	NC_000020.10, NT_011333.6	ENST00000245663, ENST00000302995, ENST00000395104	qHsaCID0021250	CAGTACGGACACTTGAACTTCTTCCTGATCACCGTGAACTCATTCAGGGACAGCGAGTGGGCCCCTCTGGGCAGGTACTCGAACAGCAGGGAGCCGTCATCCCCCAGCACGT
AKT3	NG_027811.1, NC_000001.10, NT_167186.1	ENST00000336199, ENST00000366540, ENST00000366539, ENST00000552631,	qHsaCID0036448	TTATCAATTTGTGAAGTTGGACTACAATTCATTCTCTCCTCTTCTTGCCTCTGCAGTCTGTCTGCTACAGCCTGGATAGCTTCTGTCCATTCTTCCCTTTCCTCTGGAGTATCTACATGAAATGTTC
PDGFB	NC_000022.10, NG_012111.1, NT_011520.12	ENST00000263826	qHsaCID0016004	AGCTCGCCTCCAGAGTGGGAGCGGGTCATGTTCAGGTCCAACTCGGCCCCATCTTCCTCTCCGGGGTCTCCGTGCAGCAGGCGTTGGAGATCATCAAAGGAGCGGATCGAGTGGTC
STAT3	NC_000017.10, NT_010783.15, NG_007370.1	ENST00000264657, ENST00000404395, ENST00000389272	qHsaCID0010912	GGTGTCACACAGATAAACTTGGTCTTCAGGTATGGGGCAGCGCTACCTGGGTCAGCTTCAGGATGCTCCTGGCTCTCTGGCCGACAATACTTTCCGAATGCCTCCTCCTTGGGAATGTCAGGATAGAGATAGACCAGTGGAGACACCAGGATATTGGT
STAT1	NC_000002.11, NG_008294.1, NT_005403.17	ENST00000361099, ENST00000409465, ENST00000392322, ENST00000392323,	qHsaCID0007580	TTGTCTAACATCACTGTGCTCTGAATATTCCCCGACTGAGCCTGATTAAATCTCTGGGCGTTTTCCAGAATTTTCCTTTCTTCCTTCAGACAGCTGTAAATGATCATAGACATCTGGATTGG
PDGFRβ	NC_000005.9, NG_012303.1, NG_023367.1, NT_029289.11	ENST00000261799, ENST00000544453	qHsaCID0013272	TGGTAGCTGAAGCCCACGAGGTCCATGTAGCTTAGCACTGGAGACTCGTTGATCAAAGTTGCTCGGCAGGTCCTCTCAGGGGCAGAGGGAACGTAGTTATCGTAAGGGGCCATGTAGTTGGAGGACTCGATGTCTGCATATTTGACG
HPRT1	NC_000023.10, NG_012329.1, NT_011786.16	ENST00000298556, ENST00000370796	qHsaCID0016375	GACACTGGCAAAACAATGCAGACTTTGCTTTCCTTGGTCAGGCAGTATAATCCAAAGATGGTCAAGGTCGCAAGCTTGCTGGTGAAAAGGACCCCACGAAGTGTTGGATATAAGCCAGAC
TBP	NC_000006.11, NT_025741.15, NG_008165.1	ENST00000230354, ENST00000392092, ENST00000392091, ENST00000540980	qHsaCID0007122	AAATATTGTATCCACAGTGAATCTTGGTTGTAAACTTGACCTAAAGACCATTGCACTTCGTGCCCGAAACGCCGAATATAATCCCAAGCGGTTTGCTGCGGTAATCATGAGGATAAGAGAGCCACGAACCACGGCACTGATTTTCAGTTC

Supplemental Table 3.

Table 5.

RegID	LGL type	cellularity_percent	lymphocyte_percent	CD3	CD8	M_E_ratio	Reticulin	TCR_clone	TIA_staining	Granzyme	TET2	STAT3	TNFAIP3	KMT2D	SETD1B
1715	T	NA	NA	Y	Y	NA	NA	Y	NA	NA	N	Y	N	N	N
1718	T	60	15	Y	Y	3	Zero	Y	Y	Y	N	Y	N	N	N
1849	T	65	10	Y	Y	3	Zero	Y	N	N	N	Y	N	N	N
1918	T	60	24	Y	Y	4	Zero	Y	Y	Y	N	Y	N	N	N
1948	T	30	14	Y	N	0.5	Zero	Y	NA	NA	N	N	N	N	N
1955	T	55	17	Y	Y	3	Zero	Y	NA	N	N	N	N	N	N
1960	GD	75	48	Y	Y	3	One	N	N	Y	N	N	N	N	N
1970	T	85	59	Y	Y	5	Three	Y	NA	N	N	Y	N	N	N
1973	T	60	30	Y	Y	2	Two	Y	NA	N	N	N	N	N	N
2042	T	NA	NA	Y	Y	1	NA	NA	NA	NA	N	Y	N	Y	N
2050	T	30	21	Y	Y	3	Zero	NA	NA	NA	N	N	N	N	N
2056	T	55	19	Y	Y	3	NA	Y	NA	NA	N	Y	N	N	N
2062	T	50	26	Y	Y	3	Two	Y	Y	Y	N	Y	N	N	N
2074	T	30	20	Y	Y	3	NA	Y	Y	Y	N	Y	Y	Y	Y
2080	GD	10	15	Y	Y	3	Two	Y	Y	Y	N	N	N	N	N
2083	GD	5	NA	Y	Y	3	One	Y	NA	NA	N	N	N	N	N
2084	T	80	40	Y	Y	0.4	One	N	N	N	N	Y	N	N	N
2108	T	45	NA	Y	Y	3	One	Y	Y	Y	N	Y	N	N	N
2110	T	25	34	Y	Y	0.2	Zero	Y	Y	Y	N	Y	N	N	N
2116	GD	12	39	Y	Y	3	Zero	N	N	N	N	N	N	N	N
2119	T	40	25	Y	Y	3	Zero	N	N	N	N	N	N	N	N
2122	T	30	NA	Y	Y	3	Zero	N	N	N	N	N	N	N	N
2126	T	50	42	NA	NA	4	One	Y	NA	NA	Y	Y	N	N	N
2151	T	45	33	Y	Y	3	One	N	N	N	N	Y	N	N	N
2152	T	60	25	Y	Y	NA	NA	N	N	N	N	Y	N	N	N
2169	T	45	6	Y	NA	3	One	NA	NA	NA	N	N	N	N	N
2208	GD	30	13	Y	Y	3	Zero	N	N	N	N	Y	N	N	N
2228	T	70	3	Y	Y	3	Zero	NA	NA	NA	Y	Y	N	N	Y
2247	GD	34	1	Y	NA	0.2	Zero	Y	Y	Y	N	N	N	N	N
1474	T	65	25	Y	Y	3	Zero	Y	NA	NA	N	Y	N	N	N
1499	T	70	NA	Y	Y	2	NA	Y	Y	N	N	Y	N	N	N
1544	T	40	18	Y	Y	1.4	Zero	NA	NA	NA	N	Y	Y	N	Y
1549	T	90	20	Y	Y	6	Two	Y	NA	NA	N	N	N	N	N
1726	T	80	NA	Y	Y	1	NA	Y	NA	NA	N	N	N	N	N
1733	T	45	NA	Y	Y	0.8	Zero	Y	Y	Y	N	N	N	N	N
1746	T	60	NA	Y	Y	2	One	Y	NA	NA	N	Y	N	N	N
1798	T	45	5	Y	Y	NA	One	Y	NA	NA	N	Y	N	N	N
1822	T	70	17	Y	Y	NA	NA	NA	NA	NA	N	N	N	N	N
1945	T	65	40	Y	Y	3	Zero	Y	Y	Y	N	N	N	N	N
1985	T	15	15	Y	Y	1.4	Zero	NA	NA	NA	N	Y	N	N	N
2107	T	15	NA	Y	NA	NA	NA	NA	NA	NA	N	N	N	N	N
2214	T	55	22	Y	Y	2	Zero	Y	Y	Y	N	Y	N	N	Y

Supplemental Table 5.

RegID: Patient registry ID at UVA LGL registry
Cellularity_percent: Percent of bone marrow biopsy specimen composing the volume of cells compared to the volume of other components of the bone marrow, acquired from pathology report of bone marrow biopsy
lymphocyte_percent: Percent of lymphocytes acquired from pathology report of bone marrow aspirate
CD3: Presence or absence of CD3+ lymphocytes in bone marrow aspirate
CD8: Presence or absence of CD8+ lymphocytes in bone marrow aspirate
M_E_ratio: The ratio of myeloid to erythroid precursors acquired from the pathology report of bone marrow biopsy
Reticulin: Reticulin staining of bone marrow biopsy graded on bauermeister scale as follows: 0 (absent), 1 (fine fibers), 2 (diffuse fine fiber network), 3 (diffuse fiber network with scattered coarse fibers), and 4 (areas of collagen on trichrome stain)
TCR_clone: Presence of absence of T-cell receptor clone via gamma-chain gene PCR assay
TIA_staining: Presence or absence of TIA-1 antibodies acquired from immunohistochemistry report of bone marrow biopsy specimens
Granzyme: Presence or absence of granzyme B antibodies acquired from immunohistochemistry report of bone marrow biopsy specimens
TET2 to SETD1B: Presence of somatic mutations (as indicated in the column name) in patient whole exome sequencing data. These five genes are selected based on frequency of occurrence in the cohort as a putative driver, and it's co-occurrence with STAT3 mutations.
NA values: Not available

Table 6.

RegID	Age (Years)	Sex	LGL_Type	RBC (10e6/mm3)	HCT (%)	HGB (g/dL)	WBC (10e9/L)	MCV (fL)	RDW (%)	Platelets (10e9/L)	>Neutrophils (%)	Lymphocytes (%)	ANC (k/µL)	ALC (k/µL)	Rheumatoid Arthritis (Y/N)	Treatment_at_sequencing	Treatment	Treatment Response	LGL absolute count (k/µL	TCRgdpos (%)	TCRgdposCD3pos (%)	CD3pos (%)	CD8pos (%)	CD3posCD8pos (%)	CD16pos (%)	CD3posCD16pos (%)	CD56pos (%)	CD3posCD56pos (%)	CD57pos (%)	CD3posCD57pos (%)	CD3negCD16pos (%)	CD3negCD56pos (%)	CD3negCD57pos (%)	CD94pos (%)
1474	72	M	T	4.37	40.1	13.4	6.1	91.8	14.9	166	28	65	1.71	3.97	N	N			190.56	NA	NA	NA	NA	75	NA	6	NA	6	NA	48	NA	NA	NA	NA
1499	50	F	T	4.64	38.7	13.6	2.9	83.4	13.7	145	4	86	0.12	2.49	N	Y	Cyclosporine	NR	9.96	NA	NA	NA	NA	53	NA	3	NA	4	NA	4	NA	NA	NA	NA
1544	54	F	T	4.35	38	12.9	4.6	87.4	14.7	290	13	76	0.6	3.5	N	N				NA	NA	93	76	NA	60	NA	2	NA	34	NA	NA	NA	NA	NA
1549	70	F	T	2.7	31.8	10	2.7	117.8	13.8	166	25	67	0.68	1.81	N	NA			137.56	NA	NA	95	86	84	NA	76	NA	1	NA	66	NA	NA	NA	NA
1688	59	F	T	3.95	38.7	12.6	2.5	98	12.9	150	56.1	37.5	1.4	0.94	N	N				NA	NA	NA	50	NA	NA	NA	NA	17	NA	NA	NA	NA	NA	NA
1715	44	F	T	2.74	28.4	9.9	7.7	103.6	16.5	327	5	90	0.39	6.93	N	N				NA	NA	76	NA	46	30	NA	NA	NA	50	NA	NA	NA	NA	NA
1718	59	M	T	3.19	30.8	10.4	6.58	96.6	15.9	281	15.6	76.1	1.03	5.01	N	N			275.55	NA	NA	NA	NA	75	NA	3	NA	2	NA	55	NA	NA	NA	NA
1726	76	M	GD	4.44	40	14.1	6.32	90.1	13.5	82	80.5	9.2	5.09	0.58	N	Y	Cytoxan	NE	2.9	85	NA	96	NA	15	NA	0	NA	22	NA	5	NA	NA	NA	NA
1733	64	F	T	3.66	34.9	11.3	9.79	95.4	15.1	317	32	60	3.13	5.87	Y	N			129.14	NA	NA	NA	NA	40	NA	1	NA	3	NA	22	NA	NA	NA	NA
1746	69	F	T	2.99	28.5	9.8	2.89	95.3	14.9	168	41	45	1.18	1.3	N	Y	Cyclosporine	PR	40.3	NA	NA	96	NA	72	NA	0	NA	0	NA	31	NA	NA	NA	NA
1754	59	F	T	5.16	46.2	16.2	10.89	89.5	12.7	255	48.7	43.2	5.3	4.7	N	N			267.9	NA	NA	NA	NA	54	NA	14	NA	8	NA	57	NA	NA	NA	NA
1796	59	M	T	4.47	37.8	12.4	1.65	84.6	16.9	181	12	76	0.2	1.25	Y	N			31.25	NA	NA	NA	NA	52	NA	0	NA	1	NA	25	NA	NA	NA	NA
1798	47	M	T	4.84	43.9	15.5	4.75	90.7	13.1	132	35	54.7	1.66	2.6	N	N			88.4	NA	NA	NA	NA	58	NA	0	NA	20	NA	34	NA	NA	NA	NA
1822	75	F	GD	3.27	23.7	7.3	14.2	72.5	20.9	103	NA	NA	0	0	NA	Y	Cytoxan	NE		73	NA	50	1	NA	1	NA	50	NA	1	NA	NA	NA	NA	NA
1844	61	F	T	3.83	38.1	13.3	7.5	99.5	12.2	229	26.7	65.3	2	4.9	N	N				NA	NA	94	65	NA	NA	NA	NA	NA	50	NA	NA	NA	NA	NA
1849	27	F	T	4.89	42.7	14.7	3.6	87.3	13.2	110	46	45	1.66	1.62	N	N			14.58	NA	NA	NA	NA	29	NA	0	NA	1	NA	9	NA	NA	NA	NA
1878	39	F	T	4.62	42.3	14.1	3.94	91.6	13.8	223	25.9	59.6	1.02	2.35	N	N			49.35	NA	NA	NA	NA	41	NA	0	NA	18	NA	21	NA	NA	NA	NA
1888	66	F	GD	4.53	34.5	11	3.11	76.2	16.4	109	0.4	80.4	0.01	2.5	Y	N			125	NA	58	NA	NA	68	NA	0	NA	0	NA	50	NA	NA	NA	NA
1895	70	F	T	4	35.7	12.4	9.2	89.3	13	252	55	36	5.06	3.31	N	N			99.3	NA	NA	NA	31	NA	NA	4	NA	18	NA	30	NA	NA	NA	NA
1906	55	M	T	4.4	40	14.1	3.93	90.9	13.8	158	19.3	67.2	0.76	2.64	N	N			116.16	NA	NA	NA	NA	53	NA	0	NA	0	NA	44	NA	NA	NA	NA
1918	50	F	T	2.46	26.5	8.8	14.79	107.7	17.2	184	NA	NA	0.42	13.89	N	N			958.41	NA	NA	NA	NA	96	NA	0	NA	69	NA	69	NA	NA	NA	NA
1919	54	M	T	3.98	35.3	11.9	6.06	88.7	13.7	249	51.3	35.3	3.11	2.14	N	N			68.48	NA	NA	NA	NA	45	NA	0	NA	15	NA	32	NA	NA	NA	NA
1942	29	F	T	5.02	43	14.4	3	85.7	13.2	319	34	60	1.02	1.8	N	N			34.2	NA	NA	NA	NA	43	NA	0	NA	14	NA	19	NA	NA	NA	NA
1945	64	F	T	2.85	30.7	10.5	5.6	107.7	NA	216	14	82	0.78	4.59	N	N				NA	NA	NA	NA	65	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
1948	79	M	T	3.36	30.2	9.1	4.95	89.9	16.3	243	54	30.1	2.67	1.49	N	N			83.44	NA	NA	NA	NA	31	NA	1	NA	34	NA	56	NA	NA	NA	NA
1955	71	F	T	4.82	42.9	14.1	8.92	89	14.9	37	30.8	53.5	2.75	4.77	N	N			381.6	NA	NA	NA	NA	72	NA	0	NA	6	NA	80	NA	NA	NA	NA
1960	62	M	GD	2.21	26.8	8.6	9.99	121.3	16.1	143	12.9	81.1	1.29	8.1	N	N			753.3	NA	66	NA	NA	55	NA	93	NA	0	NA	10	NA	NA	NA	NA
1970	79	F	T	2.29	25	8.2	6.76	109.2	NA	255	NA	NA	1.7	0	N	N				NA	NA	NA	NA	85	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
1973	59	M	T	3.03	32.9	10.7	13.67	108.6	16	248	6.6	88.7	0.9	12.13	N	N				NA	NA	50	50	NA	30	NA	NA	NA	30	NA	NA	NA	NA	NA
1974	33	M	T	2.4	26	8.6	2.8	108.3	19.9	214	8	83	0.22	2.32	NA	N				NA	NA	50	50	NA	1	NA	1	NA	50	NA	NA	NA	NA	NA
1985	57	M	T	4.18	38	12.5	4.7	90.9	13.8	233	15	66	0.71	3.1	N	N			77.5	NA	NA	NA	NA	47	NA	0	NA	4	NA	25	NA	NA	NA	NA
1999	65	M	T	4.6	39.6	13.9	12.43	86.1	12.7	375	22.9	65	2.85	8.08	N	N				NA	NA	NA	76	NA	2	NA	51	NA	82	NA	NA	NA	NA	NA
2009	64	F	T	4.79	40	13	8.16	83.5	14.4	265	38.9	48.3	3.17	3.94	N	N			149.72	NA	NA	NA	NA	74	NA	0	NA	44	NA	38	NA	NA	NA	NA
2018	37	F	T	3.66	35.8	12.2	10.5	97.8	15.3	403	23.5	72.4	2.47	7.6	NA	N				NA	NA	50	50	NA	65	NA	1	NA	50	NA	NA	NA	NA	NA
2020	36	M	T	4.47	40.3	13.2	3.36	90.2	14.7	80	3	29	0.1	0.97	N	N			33.756	NA	NA	NA	NA	10.5	NA	13.3	NA	2.9	NA	34.8	NA	NA	NA	NA
2022	66	M	T	4.39	39.9	13.5	3.72	90.9	14.3	152	58.9	30.9	2.19	1.15	N	Y	MTX	CR	42.55	NA	NA	NA	NA	48	NA	0	NA	4	NA	37	NA	NA	NA	NA
2024	63	F	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA				NA	NA	NA	54	NA	33	NA	9	NA	58	NA	NA	NA	NA	NA
2029	68	M	T	3.03	32.9	10.9	7.11	108.6	14.5	186	8.2	79.1	0.58	5.62	N	N			258.52	NA	NA	NA	NA	82	NA	0	NA	0	NA	46	NA	NA	NA	NA
2037	44	F	T	3.72	34.5	12.4	5.2	92.7	13.5	248	19	66	0.99	3.43	N	N			41.16	NA	NA	NA	NA	56	NA	0	NA	2	NA	12	NA	NA	NA	NA
2042	74	M	T	5.14	44.4	15.3	6.59	86.4	13.9	45	27.2	53.6	1.79	3.53	NA	N			208.27	NA	NA	NA	NA	70	NA	59	NA	1	NA	12	NA	NA	NA	NA
2049	59	F	T	4.37	36.7	12	6	84	14.6	256	17.2	74.1	1.03	4.45	N	N				NA	NA	95	NA	46	30	NA	1	NA	30	NA	NA	NA	NA	NA
2050	49	F	T	4.51	39.4	13.8	4.28	87.4	13.2	196	5.4	85.3	0.23	3.65	N	N			255.5	NA	NA	NA	NA	79	NA	70	NA	0	NA	59	NA	NA	NA	NA
2051	70	F	T	2.49	27.6	9.4	7.97	110.8	14.2	305	26.8	68.7	2.14	5.48	N	N			416.48	NA	NA	NA	NA	84	NA	0	NA	0	NA	76	NA	NA	NA	NA
2056	39	F	T	4.19	36.1	11.8	2.97	86.2	15.6	179	24	52.2	0.71	1.55	Y	Y	MTX	CR	41.85	NA	NA	NA	NA	47	NA	24	NA	1	NA	27	NA	NA	NA	NA
2062	46	M	T	2.82	26.6	8.8	3.19	94.3	19.4	74	19	24.1	0.61	0.77	N	Y	Cyclosporine	NR	23.87	NA	NA	NA	NA	85	NA	0	NA	0	NA	31	NA	NA	NA	NA
2074	57	F	T	4.18	36.9	12.4	5.67	88.3	14.2	235	16.7	73.9	0.95	4.19	N	N			201.12	NA	NA	NA	NA	66	NA	0	NA	8	NA	48	NA	NA	NA	NA
2077	13	F	T	5.6	40	12.4	3.1	71.4	15.4	261	16	80	0.5	2.48	N	Y	MTX	NE	138.88	NA	NA	NA	NA	82	NA	0	NA	0	NA	56	NA	NA	NA	NA
2080	48	M	GD	5	41.8	14.3	3.43	83.6	12.8	145	36.5	46.9	1.25	1.61	N	N			20.93	NA	49	NA	NA	70	NA	3	NA	15	NA	13	NA	NA	NA	NA
2081	46	M	T	2.35	24.3	8	2.72	103.4	21	347	30.5	58.8	0.83	1.6	N	Y	Cyclosporine	NR	86.4	NA	NA	NA	NA	73	NA	1	NA	73	NA	54	NA	NA	NA	NA
2082	66	M	T	4.48	42.8	14.5	11.06	95.5	12.9	275	36.5	38.3	4.04	4.24	N	N			237.44	NA	NA	NA	NA	78	NA	0	NA	2	NA	56	NA	NA	NA	NA
2083	65	M	GD	4.63	42.5	15.2	2.99	91.8	13.3	134	61.2	22.7	1.83	0.68	NA	N			20.4	NA	38	NA	NA	44	NA	30	NA	54	NA	NA	NA	NA	NA	NA
2084	69	M	T	5.11	42.9	14.1	5.2	84	14	131	49.7	36.3	2.58	1.89	N	N			45.36	NA	NA	NA	41	NA	NA	NA	NA	NA	NA	24	NA	NA	NA	NA
2090	56	F	GD	4.07	38.4	12.4	34.4	94.3	16.6	103	1.8	98.2	0.62	33.78	Y	Y	MTX	PR		50	NA	50	3	NA	50	NA	1	NA	50	NA	NA	NA	NA	NA
2095	64	M	T	4.44	40.8	14.1	3.25	91.9	15.7	163	19.4	58.8	0.63	1.91	Y	N			95.5	NA	NA	NA	NA	56	NA	0	NA	1	NA	50	NA	NA	NA	NA
2098	41	F	T	4.28	39.5	13.5	8.28	92.3	12.3	314	49.5	43.1	4.1	3.57	N	N			217.77	NA	NA	NA	NA	71	NA	0	NA	62	NA	61	NA	NA	NA	NA
2103	52	F	T	4.51	40.9	13.9	4.63	90.7	13.4	208	29.7	59.8	1.38	2.77	N	N			132.96	NA	NA	NA	NA	68	NA	2	NA	2	NA	48	NA	NA	NA	NA
2105	56	F	T	4.43	41.3	13.7	2.67	93.2	12.5	162	40.4	50.9	1.08	1.36	N	N			43.52	NA	NA	NA	NA	50	NA	1	NA	3	NA	32	NA	NA	NA	NA
2107	66	F	T	4.1	40.5	13.8	4.3	98.8	14.1	183	15	64	0.65	2.75	N	N				NA	NA	74.2	NA	21.2	50	NA	NA	NA	50	NA	NA	NA	NA	NA
2108	51	M	T	4.08	42	14.1	5.22	102.9	14.3	223	60.2	28.5	3.14	1.49	N	Y	Cytoxan	NE	35.76	NA	NA	NA	NA	42	NA	24	NA	1	NA	17	NA	NA	NA	NA
2110	34	F	T	3.77	37.6	12.6	2.66	99.7	15.2	144	32.7	57.5	0.87	1.53	N	N			70.38	NA	NA	NA	NA	73	NA	0	NA	0	NA	46	NA	NA	NA	NA
2116	75	F	GD	2.03	25.1	7.9	6.48	123.6	17.6	322	67.1	25	4.35	1.62	N	N			77.76	NA	23	NA	NA	70	NA	1	NA	1	NA	48	NA	NA	NA	NA
2118	25	M	T	5.13	44.2	16	3.39	86.2	11.8	278	43.4	46.6	1.47	1.58	N	N			34.76	NA	NA	NA	NA	44	NA	0	NA	4	NA	22	NA	NA	NA	NA
2119	69	F	T	3.06	31.7	10.4	3.27	103.6	15.4	54	13.2	79.5	0.43	2.6	N	N			114.4	NA	NA	NA	NA	83	NA	0	NA	2	NA	44	NA	NA	NA	NA
2120	75	M	T	2.89	28.6	9.7	3.98	99	18.5	218	47.5	32.4	1.89	1.29	N	N			42.57	NA	NA	NA	NA	72	NA	0	NA	1	NA	33	NA	NA	NA	NA
2122	71	M	T	4.24	39	13.9	3.39	92	13.6	124	26.9	51.3	0.91	1.74	N	N			41.76	NA	NA	NA	NA	44	NA	1	NA	0	NA	24	NA	NA	NA	NA
2125	70	F	T	3.9	35.3	11.8	7.74	90.5	14	197	37.4	54.1	2.89	4.19	N	N			196.93	NA	NA	NA	NA	66	NA	0	NA	0	NA	47	NA	NA	NA	NA
2126	74	M	T	2.29	24.5	8	6.31	107	16.6	405	1.8	78.6	0.11	4.96	N	N			367.04	NA	NA	NA	NA	84	NA	74	NA	0	NA	71	NA	NA	NA	NA
2127	53	F	T	4.76	41.7	13.6	26.8	87.6	NA	181	4	95	1.07	25.46	NA	NA				NA	NA	NA	67	NA	89	NA	21	NA	55	NA	NA	NA	NA	NA
2135	67	F	T	4.48	39.5	13.2	5.8	88.2	14.1	167	19.5	4.2	1.13	0.25	N	Y	MTX	NE	18	NA	NA	NA	NA	81	NA	0	NA	28	NA	72	NA	NA	NA	NA
2139	60	F	T	4.44	41.3	14	3.79	93	15	173	25.3	63.6	0.96	2.41	N	Y	MTX	NE	154.24	NA	NA	NA	NA	71	NA	0	NA	1	NA	64	NA	NA	NA	NA
2143	50	M	T	3.4	33.7	11.6	2.95	99.1	15.5	188	31.1	53.6	0.92	1.58	N	N			39.5	NA	NA	NA	NA	54	NA	0	NA	4	NA	25	NA	NA	NA	NA
2144	66	M	T	2.72	28.8	9.8	11.56	105.9	16.5	219	9.5	85.6	1.1	9.9	N	N			277.2	NA	NA	NA	NA	96	NA	0	NA	0	NA	28	NA	NA	NA	NA
2145	65	M	T	4.62	40.3	13.9	6.98	87.2	14.7	117	26.9	64.9	1.88	4.53	N	N			185.73	NA	NA	NA	NA	71	NA	0	NA	0	NA	41	13	13	9	14
2146	67	F	T	4.63	42	14.5	7.09	90.7	14	265	52.8	37.1	3.74	2.63	N	N			123.61	NA	NA	NA	NA	26	NA	0	NA	49	NA	47	NA	NA	NA	NA
2147	57	F	T	3.99	36.5	13	4.2	91.5	14.6	225	0.1	0.8	0.4	3.3	N	Y	MTX	NR		NA	NA	NA	52	NA	NA	NA	3	NA	30	NA	NA	NA	NA	NA
2151	81	M	T	3.51	33.8	11.5	10.1	96.3	17.1	72.1	18	72.1	1.82	7.28	N	N			414.96	NA	NA	NA	NA	92	NA	0	NA	0	NA	57	NA	NA	NA	NA
2152	67	M	T	2.69	26.8	8.8	6.08	99.6	16.1	287	39.6	43.8	2.41	2.66	N	N			119.7	NA	NA	NA	NA	78	NA	0	NA	0	NA	45	NA	NA	NA	NA
2153	61	F	T	5	44.4	14.7	7.31	88.8	15	184	4.5	31.2	0.33	2.28	N	Y	Cytoxan	NE	132.24	NA	NA	NA	NA	67	NA	1	NA	40	NA	58	NA	NA	NA	NA
2157	77	M	GD	2.73	30.2	10.3	7.49	110.6	18.2	303	46.2	45	3.46	3.37	NA	Y	MTX	NE	181.98	NA	54	NA	NA	82	NA	0	NA	0	NA	54	NA	NA	NA	NA
2164	57	M	T	4.96	42.1	14.4	4.13	84.9	13.9	211	19.1	61	0.79	2.52	N	N			131.04	NA	NA	NA	NA	67	NA	0	NA	2	NA	52	NA	NA	NA	NA
2165	51	F	T	4.27	40.7	13.2	3.75	95.3	16.5	311	57.4	26.1	2.15	0.98	N	Y	MTX	CR	27.44	NA	NA	NA	NA	51	NA	0	NA	10	NA	28	NA	NA	NA	NA
2169	65	M	T	4.71	42.4	14.5	6.11	90	12.7	173	43	43.9	2.63	2.68	N	N			134	NA	NA	NA	NA	59	NA	0	NA	40	NA	50	NA	NA	NA	NA
2173	55	F	T	3.33	34.9	12	2.9	104.8	15.4	294	25.5	62.1	0.74	1.8	N	N			75.6	NA	NA	NA	NA	78	NA	0	NA	0	NA	42	NA	NA	NA	NA
2174	71	F	T	4.23	38.5	13.1	5.37	91	12.2	219	67	24	3.6	1.29	N	N			24.51	NA	NA	NA	NA	41	NA	17	NA	1	NA	19	NA	NA	NA	NA
2180	53	F	T	4.08	36.6	13	6.45	89.7	17.1	93	24.8	69.5	1.6	4.48	N	N			120.96	NA	NA	NA	NA	93	NA	0	NA	3	NA	27	NA	NA	NA	NA
2183	53	M	T	4.58	42.6	14.1	6.99	93	13	214	46.7	3.3	3.26	0.23	N	N			7.82	NA	NA	NA	NA	44	NA	0	NA	3	NA	34	NA	NA	NA	NA
2186	56	F	GD	4.18	37.7	12	2.22	90.2	14	124	27.9	57.2	0.62	1.27	N	N			39.37	NA	25	NA	NA	48	NA	0	NA	0	NA	31	NA	NA	NA	NA
2188	56	M	T	4.89	42	13.8	8.29	85.9	14.1	223	5	74	0.41	6.13	N	N			337.15	NA	NA	NA	NA	81	NA	0	NA	0	NA	55	NA	NA	NA	NA
2190	44	F	T	2.87	28.5	9.3	2.67	99.3	15.6	152	29.1	50.6	0.78	1.35	N	N			36.45	NA	NA	NA	NA	54	NA	0	NA	0	NA	27	NA	NA	NA	NA
2191	52	F	T	3.84	35	11.3	2.7	91.1	15.2	156	1.5	78.9	0.04	2.13	N	Y	MTX	NE	29.82	NA	NA	NA	NA	68	NA	0	NA	0	NA	14	NA	NA	NA	NA
2194	64	F	T	4.04	40.4	13.1	6.27	100	12.7	180	43.3	48.6	2.71	3.05	N	N			91.5	NA	NA	NA	NA	52	NA	0	NA	2	NA	30	NA	NA	NA	NA
2200	56	M	T	3.87	37	13	3.09	95.6	NA	73	7.5	82.8	0.23	2.56	N	N				NA	NA	NA	NA	96	50	NA	NA	NA	30	NA	NA	NA	NA	NA
2202	38	M	T	5	43.3	14.7	12.75	86.6	13.9	122	27.4	61.9	3.49	7.89	N	N			552.3	NA	NA	NA	NA	80	NA	0	NA	0	NA	70	9	0	5	7
2204	64	F	T	3.88	38.3	13.5	10.35	98.7	14.8	338	50.1	39.8	5.19	4.12	Y	N			140.08	NA	NA	NA	NA	44	NA	0	NA	20	NA	34	NA	NA	NA	NA
2205	63	F	T	3	26	8.6	4.18	86.7	16.7	59	28.8	51.4	1.2	2.15	N	N			131.15	NA	NA	NA	NA	79	NA	0	NA	1	NA	61	NA	NA	NA	NA
2207	66	M	T	4.54	43.4	14.6	7.51	95.6	14.8	134	NA	NA	0	0	Y	N			0	NA	NA	NA	NA	57	NA	0	NA	1	NA	71	NA	NA	NA	NA
2208	48	M	GD	2.63	23.7	8	3.18	90.1	23.1	303	42.2	48.4	1.34	1.54	N	N			55.44	NA	52	NA	NA	21	NA	1	NA	1	NA	36	NA	NA	NA	NA
2214	65	F	T	5.07	42.7	14.5	3.2	84.2	14.8	168	30.6	53.7	0.98	1.72	N	N				NA	NA	91.4	NA	45.4	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
2217	63	M	T	5.16	45.7	14.5	4.53	88.6	15.3	130	34.2	55.4	1.55	2.51	N	N			122.99	NA	NA	NA	NA	58	NA	3	NA	9	NA	49	NA	NA	NA	NA
2225	54	F	T	5.02	40.2	13.9	7.7	80.1	14.1	241	13.3	64.6	1.02	4.97	N	N			258.44	NA	NA	NA	NA	81	NA	0	NA	0	NA	52	NA	NA	NA	NA
2226	63	M	T	4.07	37.1	12.4	2.2	91.2	15.5	41	7.7	84.5	0.17	1.86	N	N			89.28	NA	NA	NA	NA	70	NA	0	NA	2	NA	48	NA	NA	NA	NA
2228	60	F	T	5.34	43.7	14	12.99	81.8	16.5	136	8.7	80	1.13	10.39	N	N			862.37	NA	NA	NA	NA	78	NA	0	NA	0	NA	83	NA	NA	NA	NA
2247	43	F	GD	4.56	39.1	13.3	10.74	85.7	14.7	47	22.3	63.4	2.4	6.81	Y	N			313.26	NA	43	NA	NA	51	NA	0	NA	0	NA	46	NA	NA	NA	NA
2249	63	M	T	4.76	41.3	13.3	6.24	86.8	16.5	124	23.1	56.1	1.44	3.5	Y	N			175	NA	NA	NA	NA	66	NA	0	NA	2	NA	50	NA	NA	NA	NA
2251	71	M	T	2.83	24.5	8.1	7.09	86.6	15.7	135	10.5	71.9	0.74	5.1	N	N			331.5	NA	NA	NA	NA	94	NA	0	NA	0	NA	65	NA	NA	NA	NA

Supplemental Table 6.

LGL_Type: LGL subtype diagnosed in patient
RBC to ALC column: Complete Blood Count (CBC) parameters of patient
Rheumatoid Arthritis: Presence of concurrent Rheumatoid Arthritis
Treatment_at_sequencing: Was the patient on LGL treatment (Methotrexate, Cyclophosphamide, Cyclophosphamide) at time of sample acquisition for sequencing?
Treatment: Type of treatment received by patient (MTX = Methotrexate).
Treatment Response: Response to treatment patient received at time of sequencing.
Complete response (CR) was defined as attainment of normal CBC (ANC > 1500/mm3; lymphocyte count < 4,000/mm3; hemoglobin > 11g/dl; platelet count > 100,000/mm3). In addition, LGL counts as determined by repeat flow cytometry needed to be in the normal range.
Partial response (PR) was defined as improvement in hematologic parameters in the absence of CR: 1) ANC > 500, as long as this represented 50% increase (treatment category a); 2) improvement in ANC > 50% over baseline (treatment category b); 3) increase in hemoglobin by > 1g/dl for at least four months duration (treatment category c); and 4) decrease in monthly transfusion requirements of > 50% for at least four months duration (treatment category d).
No response (NR) was defined as lack of CR/PR.
Progressive disease (PD) was defined as worsening of hematologic parameters in patients previously achieving PR/CR.
Non-evaluable (NE): Lack of data to assess response, or patients who were treated for non-LGL.
LGL absolute count: Absolute number of LGL cells in (k/µL) calculated based on ALC counts and CD3+ CD16+ or CD3+ CD57+, which ever is higher.
TCRgdpos to CD94: Flow cytometry values of patient peripheral blood sample
NA values: Not available

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

HeeJin Cheon, BSc

Department of Biochemistry and Molecular Genetics
University of Virginia School of Medicine
University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Jeffrey C. Xing, PhD

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Katharine B. Moosic, BS

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Johnson Ung, BS

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Vivian W. Chan, MD

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

David Sukwon Chung, BS

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Mariella F. Toro, BA

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Omar Elghawy, BS

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

John S. Wang, BS

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Cait E. Hamele, BS

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Ross C. Hardison, PhD

Department of Biochemistry and Molecular Biology
Center for Computational Biology & Bioinformatics
The Pennsylvania State University
State College, Pennsylvania

Thomas L. Olson, PhD

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Su-Fern Tan, PhD

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

David J. Feith, PhD

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Aakrosh Ratan, PhD

Center for Public Health Genomics
University of Virginia
Department of Public Health Sciences
University of Virginia School of Medicine
Charlottesville Virginia

Thomas P. Loughran Jr, MD

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

CME Author

Laurie Barclay, MD

Freelance writer and reviewer
Medscape, LLC

Disclosures

Disclosure: Laurie Barclay, MD, has disclosed the following relevant financial relationships:
Stock, stock options, or bonds: AbbVie Inc. (former)

Editor

Freda K. Stevenson, PhD

Associate Editor, Blood

Disclosures

Disclosure: Freda K. Stevenson, PhD, has disclosed no relevant financial relationships.

Compliance Reviewer

Leigh A. Schmidt, MSN, RN, CMSRN, CNE, CHCP

Associate Director, Accreditation and Compliance
Medscape, LLC

Disclosures

Disclosure: Leigh A. Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.

CME / ABIM MOC

Genomic Landscape of TCRαβ and TCRγδ T-Large Granular Lymphocyte Leukemia

Authors: HeeJin Cheon, BSc; Jeffrey C. Xing, PhD; Katharine B. Moosic, BS; Johnson Ung, BS; Vivian W. Chan, MD; David Sukwon Chung, BS; Mariella F. Toro, BA; Omar Elghawy, BS; John S. Wang, BS; Cait E. Hamele, BS; Ross C. Hardison, PhD; Thomas L. Olson, PhD; Su-Fern Tan, PhD; David J. Feith, PhD; Aakrosh Ratan, PhD; Thomas P. Loughran Jr, MD
CME / ABIM MOC Released: 5/19/2022
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 5/19/2023

Start Activity

Target Audience and Goal Statement

This activity is intended for hematologists, oncologists, geneticists, and other clinicians caring for patients with large granular lymphocyte (LGL) leukemia.

The goal of this activity is for the learner to be better able to describe the landscape of nonsynonymous somatic variants in LGL leukemia exomes, potential differences of these mutational profiles across LGL leukemia subtypes, and potential associations of mutational groups with clinical features; shared and unique molecular characteristics of T and GD LGL leukemia subtypes based on putative driver genes; and the transcriptomic and somatic mutational landscape of STAT3 mutations compared with wild type to identify their distinct molecular signatures and STAT3-mutation--specific clinical associations, according to the most extensive paired exome and transcriptome study of LGL leukemia to date (N=105: 93 T-LGL and 12 GD-LGL subtypes).

Upon completion of this activity, participants will:

Describe nonsynonymous somatic variants in large granular lymphocyte (LGL) leukemia exomes, potential differences of these mutational profiles across LGL leukemia subtypes, and potential associations of mutational groups with clinical features, according to a paired exome and transcriptome study of LGL leukemia
Determine shared and unique molecular characteristics of LGL leukemia subtypes (T-LGL, where cells express ab T-cell receptor [TCR], and GD-LGL, where cells express TCRγδ) based on putative driver genes; and the transcriptomic and somatic mutational landscape of STAT3-mutated patients compared with STAT3 wild type to identify their distinct molecular signatures and STAT3-mutation–specific clinical associations, according to a paired exome and transcriptome study of LGL leukemia
Identify clinical implications of mutations and clinical features associated with LGL leukemia, according to a paired exome and transcriptome study of LGL leukemia

Disclosures

Faculty

HeeJin Cheon, BSc

Department of Biochemistry and Molecular Genetics
University of Virginia School of Medicine
University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Jeffrey C. Xing, PhD

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Katharine B. Moosic, BS

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Johnson Ung, BS

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Vivian W. Chan, MD

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

David Sukwon Chung, BS

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Mariella F. Toro, BA

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Omar Elghawy, BS

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

John S. Wang, BS

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Cait E. Hamele, BS

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Ross C. Hardison, PhD

Department of Biochemistry and Molecular Biology
Center for Computational Biology & Bioinformatics
The Pennsylvania State University
State College, Pennsylvania

Thomas L. Olson, PhD

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Su-Fern Tan, PhD

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

David J. Feith, PhD

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Aakrosh Ratan, PhD

Center for Public Health Genomics
University of Virginia
Department of Public Health Sciences
University of Virginia School of Medicine
Charlottesville Virginia

Thomas P. Loughran Jr, MD

University of Virginia Cancer Center
Department of Medicine
Division of Hematology/Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

CME Author

Laurie Barclay, MD

Freelance writer and reviewer
Medscape, LLC

Disclosures

Disclosure: Laurie Barclay, MD, has disclosed the following relevant financial relationships:
Stock, stock options, or bonds: AbbVie Inc. (former)

Editor

Freda K. Stevenson, PhD

Associate Editor, Blood

Disclosures

Disclosure: Freda K. Stevenson, PhD, has disclosed no relevant financi

Table 2.

Table 3.

Table 5.

Table 6.

Faculty and Disclosures

Faculty

HeeJin Cheon, BSc

Jeffrey C. Xing, PhD

Katharine B. Moosic, BS

Johnson Ung, BS

Vivian W. Chan, MD

David Sukwon Chung, BS

Mariella F. Toro, BA

Omar Elghawy, BS

John S. Wang, BS

Cait E. Hamele, BS

Ross C. Hardison, PhD

Thomas L. Olson, PhD

Su-Fern Tan, PhD

David J. Feith, PhD

Aakrosh Ratan, PhD

Thomas P. Loughran Jr, MD

CME Author

Laurie Barclay, MD

Editor

Freda K. Stevenson, PhD

Compliance Reviewer

Leigh A. Schmidt, MSN, RN, CMSRN, CNE, CHCP

CME / ABIM MOC

Genomic Landscape of TCRαβ and TCRγδ T-Large Granular Lymphocyte Leukemia

Target Audience and Goal Statement

Disclosures

Faculty

HeeJin Cheon, BSc

Jeffrey C. Xing, PhD

Katharine B. Moosic, BS

Johnson Ung, BS

Vivian W. Chan, MD

David Sukwon Chung, BS

Mariella F. Toro, BA

Omar Elghawy, BS

John S. Wang, BS

Cait E. Hamele, BS

Ross C. Hardison, PhD

Thomas L. Olson, PhD

Su-Fern Tan, PhD

David J. Feith, PhD

Aakrosh Ratan, PhD

Thomas P. Loughran Jr, MD

CME Author

Laurie Barclay, MD

Editor

Freda K. Stevenson, PhD